Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 14, 2008
- 70 Amlodipine Generics Listed from 34 Companies
July 14, 2008
- Initial Goals in Action Program for Generics Almost Met
July 14, 2008
- Pharmacists Explain Generics to Only 11% of Patients: Survey
July 14, 2008
- GENERICS NEWS IN BRIEF
July 14, 2008
- Armala May Outperform Sutent: ASCO 2008 Key Highlight Seminar
July 14, 2008
- Pfizer's Research Center Split Off to Create RaQualia
July 14, 2008
- 2008 Innovative DDS
July 14, 2008
- Prefilled Syringes Launched for Enbrel
July 14, 2008
- R&D NEWS IN BRIEF
July 14, 2008
- Takeda Completes US Business Consolidation by Merging TAP
July 14, 2008
- Takeda Files NDA for Panitumumab
July 14, 2008
- Chugai Aims at Top Share with Actemra
July 14, 2008
- Council Recommends Introduction of Reference Price System
July 14, 2008
- Shionogi, DSP Start Marketing Irbesartan
July 14, 2008
- SCJ Calls For Revision of Medical Expenditure Curtailment Policy
July 14, 2008
- Ferring to Start Independent Business by Copromoting Desmopressin with Kyowa Hakko
July 14, 2008
- REGULATORY NEWS IN BRIEF
July 14, 2008
- INTERPHEX JAPAN 2008
July 14, 2008
- MEDICAL DEVICE NEWS IN BRIEF
July 14, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…